Trial Profile

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mecasermin (Primary)
Indications Short stature
Focus Adverse reactions
Sponsors Ipsen

Most Recent Events

06 Mar 2023 Planned End Date changed from 1 Dec 2027 to 31 Dec 2027.
06 Mar 2023 Planned primary completion date changed from 1 Dec 2027 to 31 Dec 2027.
06 Dec 2021 Planned number of patients changed from 330 to 500.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com